Literature DB >> 12686010

Antiphospholipid Antibody Syndrome.

Elena Cucurull1, Azzudin E. Gharavi, Yamini Menon, Wendell A. Wilson.   

Abstract

Antiphospholipid antibody syndrome (APS) is a recently defined autoimmune disorder characterized by recurrent vascular thromboses or recurrent pregnancy morbidity; these features are linked to the presence in blood of autoantibodies against negatively charged phospholipids or phospholipid-binding proteins. Thrombosis can occur in any tissue, in veins, arteries, or the microvasculature. Pregnancy morbidity in APS includes miscarriages or premature birth. Criteria that define the major clinical and laboratory features of APS were published in 1999. In patients with antiphospholipid antibodies and prior thrombosis or pregnancy morbidity, there is a high risk of recurrence that persists as long as antiphospholipid antibodies occur in blood. This risk for recurrence of thrombosis or pregnancy morbidity is greatly reduced by preventive anticoagulant therapy. Patients presenting with thrombosis in APS are initially managed in much the same way as are patients with vascular thrombosis owing to other causes. However, in patients with APS, high-intensity anticoagulation is usually needed to prevent recurrences of thrombosis. Thrombosis in APS is often multifactorial, as with non-APS thrombosis. Therefore, in all patients with APS, other reversible risk factors for thrombosis should be sought. The pregnancy outcome of women with APS who have had prior miscarriages is greatly improved by treatment during pregnancy with a combination of heparin and low-dose aspirin.

Entities:  

Year:  2003        PMID: 12686010     DOI: 10.1007/s11936-003-0021-0

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  34 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

Review 2.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

3.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients.

Authors:  N M Shah; M A Khamashta; T Atsumi; G R Hughes
Journal:  Lupus       Date:  1998       Impact factor: 2.911

Review 4.  Low-molecular-weight heparins.

Authors:  J I Weitz
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

5.  Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.

Authors:  G Castellino; M J Cuadrado; T Godfrey; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 6.  Management of thrombosis in antiphospholipid antibody syndrome.

Authors:  M Petri
Journal:  Rheum Dis Clin North Am       Date:  2001-08       Impact factor: 2.670

Review 7.  Primary stenting in a patient with acute myocardial infarction and primary antiphospholipid syndrome.

Authors:  Ozer Badak; Sema Güneri; Onder Kirimli; Ozhan Göldeli; Ozgür Aslan; Hayri Ozsan
Journal:  J Invasive Cardiol       Date:  2002-04       Impact factor: 2.022

8.  Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS).

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

9.  Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.

Authors:  L J Crofford; J C Oates; W J McCune; S Gupta; M J Kaplan; F Catella-Lawson; J D Morrow; K T McDonagh; A H Schmaier
Journal:  Arthritis Rheum       Date:  2000-08

10.  Antiphospholipid antibodies and venous thromboembolism.

Authors:  J S Ginsberg; P S Wells; P Brill-Edwards; D Donovan; K Moffatt; M Johnston; P Stevens; J Hirsh
Journal:  Blood       Date:  1995-11-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.